View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 23, 2018updated 12 Jul 2022 1:12pm

DrugCendR begins CEND1-001 trial for pancreatic cancer

DrugCendR has started the Phase l CEND1-001 trial to examine the safety, tolerability, and biologic activity of CEND-1 in combination with nabpaclitaxel and gemcitabine to treat patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

DrugCendR has started the Phase l CEND1-001 trial to examine the safety, tolerability, and biologic activity of CEND-1 in combination with nabpaclitaxel and gemcitabine to treat patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The open-label, multicentre, dose-escalation, safety, pharmacodynamic, and pharmacokinetic trial intends to enrol 34 PDAC patients being treated with combination therapy of nabpaclitaxel and gemcitabine.

As part of the trial, the patients will receive the study combination weekly for three weeks followed by one week off over 28 days.

The trial will include an initial dose-escalation phase with three different CEND-1 dose levels, first as a monotherapy, which will be followed by combination therapy with nabpaclitaxel and gemcitabine.

It will also feature a subsequent expansion phase with around 28 subjects to evaluate the safety, tolerability and preliminary efficacy of the combination treatment using two different CEND-1 dose levels.

“Cancer cells hijack processes they can use to fuel tumour growth, and the CendR pathway is one such route.”

Primary endpoints of the CEND1-001 trial are safe doses of CEND-1 when given alone or in combination with nabpaclitaxel and gemcitabine, and optimal Biological Dose (OBD) of CEND-1 when administered in combination.

The trial’s secondary endpoints include pharmacokinetics, disease control rate, preliminary evidence of anti-tumour activity of CEND-1 and others.

DrugCendR founder, president and CEO Erkki Ruoslahti said: “Cancer cells hijack processes they can use to fuel tumour growth, and the CendR pathway is one such route.

“CEND-1 activates the CendR pathway only in tumours and not elsewhere in the body, and that allows us to sneak in a drug into the activated pathway.”

Ruoslahti discovered CEND-1, a peptide that homes in on tumours using a multi-step process, at his laboratory at Sanford Burnham Prebys Medical Discovery Institute (SBP) in the US.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena